Introduction: Congenital diaphragmatic hernia (CDH) is a complex pathology with severe pulmonary morbidity. Administration of surfactant in CDH is controversial, and the advent of fetoscopic endoluminal tracheal occlusion (FETO) has added further complexity. While FETO has been shown to improve survival outcomes, there are risks of prematurity and potential surfactant deficiency. We aim to evaluate the characteristics and outcomes of surfactant administration for CDH infants and elucidate potential benefits or risks in this unique population.
Methods: A single-center retrospective cohort review of patients with unilateral CDH from September 2015 to July 2022 was performed. Demographics, prognostic perinatal imaging features, and outcomes were collected. Patients were stratified by surfactant administration and history of FETO. Data were analyzed with descriptive statistics, two-sample t-tests, chi-squared analyses, and logistic regression.
Results: Of 105 included patients, 19 (18%) underwent FETO and 25 (24%) received surfactant. Overall, surfactant recipients were born at earlier gestational ages and lower birthweights regardless of FETO history. Surfactant recipients possessed significantly worse prenatal prognostic features such as observed to expected total fetal lung volume, observed to expected lung to head ratio, and percent liver herniation. In CDH patients without FETO history, surfactant recipients demonstrated worse outcomes than nonrecipients. This association is notably absent in the FETO population, where surfactant recipients have more favorable survival and comparable outcomes. When controlling for defect severity or surfactant usage, as a proxy for respiratory status, surfactant recipients that underwent FETO trended toward improved survival and decreased ECMO use.
Conclusions: Surfactant administration is not associated with increased morbidity and mortality and may be beneficial in CDH patients that have undergone FETO.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jss.2023.12.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Immunogenicity and safety of the MF59-adjuvanted seasonal influenza vaccine in non-elderly adults: A systematic review and meta-analysis.
PLoS One
January 2025
Seqirus S.r.l., Monteriggioni (Siena), Italy.
Objective: In Europe, the age indication for the MF59-adjuvanted quadrivalent influenza vaccine (aQIV) has recently been extended from ≥65 to ≥50 years. Considering that the earliest approval of its trivalent formulation (aTIV) in Italy was for people aged ≥12 years, we aimed to systematically appraise data on the immunogenicity, efficacy, and safety of aTIV/aQIV in non-elderly adults.
Methods: A systematic literature review was conducted according to the available guidelines and studies were searched in MEDLINE, Biological Abstracts, Web of Science, Cochrane Library and clinical trial registries.
Polyelectrolytes Are Effective Cryoprotectants for Extracellular Vesicles.
ACS Appl Mater Interfaces
December 2024
Department of Cell Biology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, 30-387 Krakow, Poland.
Extracellular vesicles (EVs) have been widely recognized as a heterogeneous group of membrane-coated submicrometer particles released by different types of cells, including stem cells (SCs). Due to their ability to harbor and transfer bioactive cargo into the recipient cells, EVs have been reported as important paracrine factors involved in the regulation of a variety of biological processes. Growing data demonstrate that EVs may serve as potential next-generation cell-free therapeutic factors.
View Article and Find Full Text PDFAdvanced MicroRNA delivery for lung inflammatory therapy: surfactant protein A controls cellular internalisation and degradation of extracellular vesicles.
Thorax
December 2024
Department of Biology and Chemistry, Changwon National University, Changwon, South Korea
Introduction: Alveolar macrophages (AMs) are the first line of defence against pathogens that initiate an inflammatory response in the lungs and exhibit a strong affinity for surfactant protein A (SP-A). Extracellular vesicles (EVs) have emerged as a promising drug delivery platform due to their minimal cytotoxicity. However, precise targeting of specific cell types and the rapid lysosomal degradation of EVs within recipient cells remain persistent challenges.
View Article and Find Full Text PDFPhysiological Modeling of the Vascularized Human Lung Organoid.
Am J Respir Cell Mol Biol
November 2024
University of Illinois At Chicago, Chicago, Illinois, United States;
Studies using human lung organoids (hLO) have focused on differentiation of lung epithelial subtypes into distal alveolar unit. A major question has been whether introducing endothelial cells (EC) and resultant vascularization alter development of hLO. We describe herein a method for vessel infiltration of hLO in which we determined differences of these hLOs with standard avascular hLOs.
View Article and Find Full Text PDFSimilar humoral responses but distinct CD4 T cell transcriptomic profiles in older adults elicited by MF59 adjuvanted and high dose influenza vaccines.
Sci Rep
October 2024
Department of Internal Medicine, Vaccine Research Group, Mayo Clinic, Rochester, MN, 55905, USA.
Article Synopsis
- - Older adults (65+) often have weaker responses to flu vaccines, leading to the recommendation of special vaccines like MF59-adjuvanted (MF59Flu) and high-dose (HDFlu) vaccines for this age group in the U.S.
- - A study analyzed gene expression in CD4 T cells from 234 older vaccine recipients before and after vaccination, finding numerous differentially expressed genes (DEGs) that varied between MF59Flu and HDFlu recipients.
- - Interestingly, the identified DEGs did not significantly correlate with immune responses against the flu virus, indicating that other factors might be at play when it comes to flu immunity in older adults.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!